PPV safe for irradiated uveal melanoma


Pars plana vitrectomy is safe to use on patients with plaque-irradiated uveal melanoma.

Pars plana vitrectomy is safe to use on patients with plaque-irradiated uveal melanoma, according to a study in the Archives of Ophthalmology.

The retrospective case series, headed by Dr Alok S. Bansal, Department of Immunology, St Helier Hospital, Carshalton, Surrey, UK, included 47 eyes of 47 patients with plaque-irradiated posterior uveal melanoma who underwent PPV for vitreous haemorrhage.

The primary outcome measures included rates of intraocular melanoma dissemination, extrascleral extension of melanoma, local melanoma recurrence and systemic melanoma metastasis after PPV.

No cases of intraocular melanoma dissemination or extrascleral extension of melanoma were found. Local choroidal melanoma recurrence was found in one patient and was successfully managed with transpupillary thermotherapy.

After a mean interval of five years after plaque radiotherapy, four patients experienced systemic melanoma metastasis. The management of vitreous haemorrhage using PPV is safe and doesn’t increase the risk of intraocular, local, orbital or systemic dissemination of the tumour in patients with uveal melanoma.

To read the abstract please click here.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.